MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.amjcard.2026.08.034

Медицинская библиотека · The American journal of cardiology · 2026

Noninvasive Hemodynamic and Echocardiographic Changes Following Vericiguat Initiation in Heart Failure With Reduced Ejection Fraction: A Prospective Registry Study.

Bocchino Pier Paolo, Carbonaro Carla, Gallone Guglielmo, Galli Gianluca, Gobello Giulia, Angelini Filippo, Griffith Brookles Carola, Bertello Eleonora, Pidello Stefano, De Lio Giulia, Ravera Francesco, Boretto Paolo, Gravinese Carol, Frea Simone, Raineri Claudia, De Ferrari Gaetano Maria

СтатьяПеревод в очереди

Аннотация

Vericiguat reduces cardiovascular death and heart failure (HF) hospitalization in high-risk patients with HF and reduced ejection fraction (HFrEF), but its noninvasive hemodynamic and remodelling effects in real-world practice remain incompletely characterized. We aimed to evaluate changes in noninvasive hemodynamic surrogates and cardiac remodeling parameters 6 months after vericiguat initiation in patients with HFrEF. We conducted a prospective, single-center study of consecutive patients with chronic HFrEF initiating vericiguat while receiving stable, optimized guideline-directed medical therapy. Coprimary endpoints were paired 6-month changes in left ventricular ejection fraction (LVEF) and left ventricular outflow tract (LVOT) velocity-time integral (VTI). Echocardiograms were analyzed blinded to subsequent clinical outcomes. An exploratory "responder" phenotype was defined by improvement in ≥1 of LVEF (increase >2%), LVOT VTI (increase >1 cm), or E/e' (reduction >1), without deterioration in the remaining indices. Clinical events were assessed using a 6-month landmark analysis. Among 113 patients (age 64 ± 11; median N-terminal pro B-type natriuretic peptide 1,433 pg/ml; baseline LVEF 28% ± 7.5%, average use of 4 pillars of guideline-directed medical therapy 94%), LVEF increased from 28% ± 7.5% to 29.8% ± 8% (p = 0.002); LVOT VTI from 16 ± 3.4 to 16.8 ± 4.1 cm (p = 0.009) at 6 months. E/e' decreased from 13.3 ± 5.3 to 11.9 ± 5.1 (exploratory; p = 0.036), and N-terminal pro B-type natriuretic peptide levels declined (p <0.001). Responder patients experienced fewer clinical events after the 6-month landmark (p = 0.013). In conclusion, among real-world optimally treated patients with HFrEF, vericiguat initiation was associated with modest but statistically significant improvements in LVEF and LVOT VTI at 6 months. Favorable echocardiographic hemodynamic response appeared associated with improved subsequent clinical outcomes, supporting the role of noninvasive hemodynamic phenotyping to characterize response to soluble guanylate cyclase stimulation.

Для цитирования: Bocchino Pier Paolo, Carbonaro Carla, Gallone Guglielmo, Galli Gianluca, Gobello Giulia, Angelini Filippo, Griffith Brookles Carola, Bertello Eleonora, Pidello Stefano, De Lio Giulia, Ravera Francesco, Boretto Paolo, Gravinese Carol, Frea Simone, Raineri Claudia, De Ferrari Gaetano Maria. Noninvasive Hemodynamic and Echocardiographic Changes Following Vericiguat Initiation in Heart Failure With Reduced Ejection Fraction: A Prospective Registry Study.. The American journal of cardiology. 2026. DOI: 10.1016/j.amjcard.2026.08.034.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.